Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism

Imagem de Miniatura
Arquivos
art_V_Testosterone_therapy_for_women_with_low_sexual_desire_2019.PDF (148.17 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2019
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
Autores
V, Rita Weiss
HOHL, Alexandre
ATHAYDE, Amanda
PARDINI, Dolores
OLIVEIRA, Monica de
MEIRELLES, Ricardo
CLAPAUCH, Ruth
SPRITZER, Poli Mara
Citação
ARCHIVES OF ENDOCRINOLOGY METABOLISM, v.63, n.3, p.190-198, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To summarize current evidence regarding testosterone treatment for women with low sexual desire. Materials and methods: The Female Endocrinology and Andrology Department of the Brazilian Society of Endocrinology and Metabolism invited nine experts to review the physiology of testosterone secretion and the use, misuse, and side effects of exogenous testosterone therapy in women, based on the available literature and guidelines and statements from international societies. Results: Low sexual desire is a common complaint in clinical practice, especially in postmenopausal women, and may negatively interfere with quality of life.Testosterone seems to exert a positive effect on sexual desire in women with sexual dysfunction, despite a small magnitude of effect, a lack of long-term safety data, and insufficient evidence to make a broad recommendation for testosterone therapy. Furthermore, there are currently no testosterone formulations approved for women by the relevant regulatory agencies in the United States, Brazil, and most other countries, and testosterone formulations approved for men are not recommended for use by women. Conclusion: Therefore, testosterone therapy might be considered if other strategies fail, but the risks and benefits must be discussed with the patient before prescription.
Palavras-chave
Testosterone therapy, female sexual disorder, position
URI
https://observatorio.fm.usp.br/handle/OPI/33244
Referências
  1. Abdo CHN, 2010, MENOPAUSE, V17, P1114, DOI 10.1097/gme.0b013e3181e19755
  2. ABRAHAM GE, 1974, J CLIN ENDOCR METAB, V39, P340, DOI 10.1210/jcem-39-2-340
  3. Achar S, 2010, AM J CARDIOL, V106, P893, DOI 10.1016/j.amjcard.2010.05.013
  4. Achilli C, 2017, FERTIL STERIL, V107, P475, DOI 10.1016/j.fertnstert.2016.10.028
  5. Alkatib AA, 2009, J CLIN ENDOCR METAB, V94, P3676, DOI 10.1210/jc.2009-0672
  6. American Psychiatric Association, 2013, DIAGN STAT MAN MENT
  7. Ankarberg C, 1999, J CLIN ENDOCR METAB, V84, P975, DOI 10.1210/jc.84.3.975
  8. [Anonymous], LEVELS EVIDENCE GRAD
  9. Arlt W, 2006, EUR J ENDOCRINOL, V154, P1, DOI 10.1530/eje.1.02062
  10. Bachmann G, 2002, FERTIL STERIL, V77, P660, DOI 10.1016/S0015-0282(02)02969-2
  11. Basson R, 2010, MENOPAUSE, V17, P962, DOI 10.1097/gme.0b013e3181d59765
  12. Bernini GP, 1999, J CLIN ENDOCR METAB, V84, P2008, DOI 10.1210/jc.84.6.2008
  13. Blouin K, 2008, J STEROID BIOCHEM, V108, P272, DOI 10.1016/j.jsbmb.2007.09.001
  14. Both S, 2017, CURR SEX HLTH REP, V9, P192
  15. Brotto LA, 2017, FRONT NEUROENDOCRIN, V45, P11, DOI 10.1016/j.yfrne.2017.02.001
  16. Bui HN, 2013, STEROIDS, V78, P96, DOI 10.1016/j.steroids.2012.10.010
  17. Burger HG, 2000, J CLIN ENDOCR METAB, V85, P2832, DOI 10.1210/jc.85.8.2832
  18. Burger HG, 2002, FERTIL STERIL, V77, pS3
  19. Burger HG, 2002, BEST PRACT RES CL OB, V16, P383, DOI 10.1053/beog.2001.0281
  20. Clayton AH, 2018, MAYO CLIN PROC, V93, P467, DOI 10.1016/j.mayocp.2017.11.002
  21. Clayton AH, 2009, J SEX MED, V6, P730, DOI 10.1111/j.1743-6109.2008.01153.x
  22. Davis SR, 2008, NEW ENGL J MED, V359, P2005, DOI 10.1056/NEJMoa0707302
  23. Davis SR, 2016, J SEX MED, V13, P168, DOI 10.1016/j.jsxm.2015.12.033
  24. Davis SR, 2015, LANCET DIABETES ENDO, V3, P980, DOI 10.1016/S2213-8587(15)00284-3
  25. Davis SR, 2009, J CLIN ENDOCR METAB, V94, P4907, DOI 10.1210/jc.2009-1523
  26. Davison SL, 2005, J CLIN ENDOCR METAB, V90, P3847, DOI 10.1210/jc.2005-0212
  27. Dennerstein L, 2005, FERTIL STERIL, V84, P174, DOI 10.1016/j.fertnstert.2005.01.119
  28. Elraiyah T, 2014, J CLIN ENDOCR METAB, V99, P3536, DOI 10.1210/jc.2014-2261
  29. HAMERS AA, 2017, WOMENS MIDLIFE HLTH, V37
  30. Handelsman DJ, 2008, BRIT J PHARMACOL, V154, P598, DOI 10.1038/bjp.2008.150
  31. Hartgens F, 2004, SPORTS MED, V34, P513, DOI 10.2165/00007256-200434080-00003
  32. Hofling M, 2007, MENOPAUSE, V14, P183, DOI 10.1097/01.gme.0000232033.92411.51
  33. Karim R, 2008, J CLIN ENDOCR METAB, V93, P131, DOI 10.1210/jc.2007-1738
  34. Klinge CM, 2018, VITAM HORM, V108, P1, DOI 10.1016/bs.vh.2018.02.002
  35. Labrie F, 2017, MENOPAUSE, V24, P702, DOI 10.1097/GME.0000000000000808
  36. Legro RS, 2010, J CLIN ENDOCR METAB, V95, P5305, DOI 10.1210/jc.2010-1123
  37. LONGCOPE C, 1986, CLIN ENDOCRINOL META, V15, P213, DOI 10.1016/S0300-595X(86)80021-4
  38. Maeda SS, 2018, ARCH ENDOCRIN METAB, V62, P106, DOI 10.20945/2359-3997000000015
  39. Maturana MA, 2011, MATURITAS, V70, P395, DOI 10.1016/j.maturitas.2011.09.012
  40. McCabe MP, 2016, J SEX MED, V13, P135, DOI 10.1016/j.jsxm.2015.12.019
  41. McCarthy AM, 2013, GYNECOL ONCOL, V129, P559, DOI 10.1016/j.ygyno.2013.02.016
  42. Montalcini T, 2012, ENDOCRINE, V42, P514, DOI 10.1007/s12020-012-9692-1
  43. Mudali S, 2005, J CLIN ENDOCR METAB, V90, P1202, DOI 10.1210/jc.2004-0744
  44. Murphy KG, 2005, J NEUROENDOCRINOL, V17, P519, DOI 10.1111/j.1365-2826.2005.01328.x
  45. Nachtigall L, 2011, GYNECOL ENDOCRINOL, V27, P39, DOI 10.3109/09513590.2010.487597
  46. Ness RB, 2009, ARCH INTERN MED, V169, P41, DOI 10.1001/archinternmed.2008.507
  47. Nobrega LHC, 2009, ARQ BRAS ENDOCRINOL, V53, P1040, DOI 10.1590/S0004-27302009000800020
  48. O'Loughlin JI, 2018, J SEX RES, V55, P734, DOI 10.1080/00224499.2017.1386764
  49. Onakomaiya MM, 2016, PSYCHOPHARMACOLOGY, V233, P549, DOI 10.1007/s00213-015-4193-6
  50. Parish SJ, 2016, J SEX MED, V13, P1888, DOI 10.1016/j.jsxm.2016.09.020
  51. Perelman MA, 2016, MANAGEMENT SEXUAL DY, P137
  52. Pope HG, 2014, ENDOCR REV, V35, P341, DOI 10.1210/er.2013-1058
  53. Reed BG, 2016, IN J WOMENS HEALTH, V8, P599, DOI 10.2147/IJWH.S116212
  54. Reed GM, 2016, WORLD PSYCHIATRY, V15, P205, DOI 10.1002/wps.20354
  55. Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864
  56. Salmon UJ, J CLIN ENDOCRINOL ME, V3, P235
  57. Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509
  58. Shifren JL, 2006, MENOPAUSE, V13, P770, DOI 10.1097/01.gme.0000227400.60816.52
  59. Shifren JL, 2014, MENOPAUSE, V21, P1038, DOI [10.1097/GME.0000000000000319, 10.1097/gme.0000000000000319]
  60. Simon JA, 2018, CLIMACTERIC, V21, P415, DOI 10.1080/13697137.2018.1482647
  61. Spoletini I, 2014, CLIMACTERIC, V17, P625, DOI 10.3109/13697137.2014.887669
  62. Stanczyk FZ, 2007, CANCER EPIDEM BIOMAR, V16, P1713, DOI 10.1158/1055-9965.EPI-06-0765
  63. Tamimi RM, 2006, ARCH INTERN MED, V166, P1483, DOI 10.1001/archinte.166.14.1483
  64. Thienpont LM, 2008, CLIN CHEM, V54, P1290, DOI 10.1373/clinchem.2008.105841
  65. Torrens JI, 2009, MENOPAUSE, V16, P257, DOI 10.1097/gme.0b013e318185e249
  66. Traish A, 2007, J SEX MED, V4, P1223, DOI 10.1111/j.1743-6109.2007.00584.x
  67. Tuiten A, 2018, J SEX MED, V15, P201, DOI 10.1016/j.jsxm.2017.11.226
  68. Wierman ME, 2014, J CLIN ENDOCR METAB, V99, P3489, DOI 10.1210/jc.2014-2260
  69. Wierman ME, 2010, J SEX MED, V7, P561, DOI 10.1111/j.1743-6109.2009.01629.x
  70. Yasui T, 2012, J MED INVESTIG, V59, P12, DOI 10.2152/jmi.59.12
  71. Zendjabil M, 2016, ANN ENDOCRINOL-PARIS, V77, P43, DOI 10.1016/j.ando.2016.01.004

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/42